Saudi Arabia’s General Authority for Military Industries Announces a Fully Integrated Defense Show Starting March 2022
17.7.2020 00:05:00 EEST | Business Wire | Press release
Today the Kingdom of Saudi Arabia’s General Authority for Military Industries (GAMI) announced the launch of ‘World Defense Show’. The show will take center stage in the global defense show circuit, offering exhibitors and visitors the opportunity to participate in Saudi Arabia’s first truly integrated defense show.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716006046/en/
His Excellency Ahmad Al Ohali, Governor of GAMI (Photo: AETOSWire)
Founded by GAMI, World Defense Show is focused on interoperability across air, land, sea, security innovative defense technologies and satellite defense systems. The inaugural event is scheduled to take place between 6th and 9th March 2022 and will then be held biennially in Saudi Arabia’s capital, Riyadh.
Speaking at a virtual press conference attended by international defense companies, GAMI’s Governor, His Excellency Ahmad Al Ohali stated: “As Technology is accelerating the rate at which the global defense industry is evolving, defense considerations are becoming increasingly complex. There is a need for a platform, which enables the defense community to convene and collectively consider the great opportunities and challenges that are facing us all. This is why we are launching World Defense Show, an innovative platform showcasing, through both live and virtual demonstrations, the possibilities that interoperability can provide across all five defense domains: Air, Land, Sea, Security and Satellite.”
He added, “There is no better place than Saudi Arabia to organize a defense event at this scale. A G20 country, the Kingdom is one of the world’s biggest defense spenders with a strategic location at the center of three continents, making it an ideal hub for defense trade and innovation. Saudi Arabia’s vision to localize 50% of its multi-billion-dollar defense expenditure by 2030 also presents massive opportunities to global industry OEMs and investors.”
GAMI has recruited a team of international experts to organize and run event operations.
Shaun Ormrod, Chief Executive Officer, World Defense Show, said: “Today’s launch of World Defense Show marks an exciting inflection point for the defense industry and a step forward in the ambition and scale of a defense trade show. Through World Defense Show we will demonstrate why Saudi Arabia is critical to the defense industry’s future. The platform will enable access to dedicated programs that support Saudi Arabia’s local businesses, it will leverage investment opportunities and encourage a new generation to aspire to work in the defense industry.” Mr. Ormrod is the former CEO of Farnborough Airshow with over 20 years of industry trade show expertise.
Over four days, World Defense Show will showcase comprehensive and interactive displays of integrated defense technology solutions, alongside conferences and thought leadership seminars focused on the next generation of defense. The show’s venue, estimated to accommodate 80,000 square meters of exhibition, hospitality and outdoor area, will feature demonstration facilities and virtual technological capabilities to showcase every defense domain on an unprecedented scale.
Video News Release embed and download link here
About World Defense Show
World Defense Show is a display and demonstration of integrated and innovation-driven defense solutions, set to serve as the global stage for defense interoperability. The inaugural World Defense Show will take place biannually starting March 2022 in Riyadh - Saudi Arabia, to showcase the latest in interoperable defense solutions. The event will be held in the presence of Saudi Arabia’s key leadership, international delegations and prominent industry decision makers from around the world.
About General Authority for Military Industries
The founder of World Defense Show, Saudi Arabia’s General Authority for Military Industries, is the regulator, enabler and licensor for the kingdom’s military industry. GAMI is responsible for domestic defense sector development in line with the national commitment to localize 50% of military manufacturing by 2030.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716006046/en/
Contact information
Yara Abifaker, +971544285342
yara.abifaker@finsbury.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 15:40:00 EEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 15:30:00 EEST | Press release
ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document processing and recognition technology, which uses advanced machine learning to process large volumes of documents with high speed and accuracy, helping organizations detect fraud earlier, prevent losses and improve outcomes. The combined business becomes one of the largest AI-native digital trust infrastructures serving regulated industries, with more than 300 enterprise customers and more than 110 billion digital interactions processed annually across the U.S., Europe, the Middle East and Australia. Customers include many of the world's
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 15:04:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every aspect of well delivery through a technology-enabled operating model. It combines digital drilling workflows with au
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 15:03:00 EEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 14:00:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanserin demonstrated a change of -12.6 versus a -10.4 change for placebo at week 6, yielding a standardized effect size of 0.26 (p=0.0603). For the key secondary endpoint, Clinical Global Impression – Severity (CGI-S-ADP), the 60 mg dose achieved a change from baseline of -1.3 versus a change of -0.9 for placebo at week 6, yielding a standardized effect size of 0.37 [p=0.0077 (nominal)]. On both efficacy measures, the difference in the 60 mg dose versus placebo increased through the 6-week treatment period. The 30 mg dose showe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom